IL268291A - Multiple transgene recombinant adenovirus - Google Patents

Multiple transgene recombinant adenovirus

Info

Publication number
IL268291A
IL268291A IL268291A IL26829119A IL268291A IL 268291 A IL268291 A IL 268291A IL 268291 A IL268291 A IL 268291A IL 26829119 A IL26829119 A IL 26829119A IL 268291 A IL268291 A IL 268291A
Authority
IL
Israel
Prior art keywords
recombinant adenovirus
multiple transgene
transgene recombinant
adenovirus
transgene
Prior art date
Application number
IL268291A
Other languages
English (en)
Hebrew (he)
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of IL268291A publication Critical patent/IL268291A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL268291A 2017-01-30 2019-07-28 Multiple transgene recombinant adenovirus IL268291A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452342P 2017-01-30 2017-01-30
US201762520945P 2017-06-16 2017-06-16
PCT/US2018/016032 WO2018140973A1 (en) 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus

Publications (1)

Publication Number Publication Date
IL268291A true IL268291A (en) 2019-09-26

Family

ID=62978741

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268291A IL268291A (en) 2017-01-30 2019-07-28 Multiple transgene recombinant adenovirus

Country Status (12)

Country Link
US (1) US20190352616A1 (cg-RX-API-DMAC7.html)
EP (1) EP3574090A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020505049A (cg-RX-API-DMAC7.html)
KR (1) KR20190128634A (cg-RX-API-DMAC7.html)
CN (1) CN110741080A (cg-RX-API-DMAC7.html)
AU (1) AU2018213417A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019015600A2 (cg-RX-API-DMAC7.html)
CA (1) CA3052090A1 (cg-RX-API-DMAC7.html)
IL (1) IL268291A (cg-RX-API-DMAC7.html)
MX (1) MX2019008921A (cg-RX-API-DMAC7.html)
SG (1) SG11201906973TA (cg-RX-API-DMAC7.html)
WO (1) WO2018140973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
JP7245175B2 (ja) * 2017-05-24 2023-03-23 エピセントアールエックス，インコーポレイテッド 抗脈管形成アデノウイルス
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
US20250177509A1 (en) * 2020-07-06 2025-06-05 Jiaxing Anyu Biotechnology Co., Ltd Recombinant adenovirus vaccine for african swine fever and method for constructing same
WO2022246646A1 (zh) * 2021-05-25 2022-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
CN113249342B (zh) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100896483B1 (ko) * 2007-07-13 2009-05-08 연세대학교 산학협력단 Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
DK3029144T3 (da) * 2009-03-02 2019-10-21 Univ California Tumorselektive adenovirus e1a- og e1b-mutanter
RU2612788C2 (ru) * 2010-03-23 2017-03-13 Интрексон Корпорейшн Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
CA2812093A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
AU2013214776B2 (en) * 2012-02-02 2017-11-09 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
CA2909432C (en) * 2013-04-18 2025-11-18 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
JP6764859B2 (ja) * 2014-09-24 2020-10-07 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Also Published As

Publication number Publication date
EP3574090A1 (en) 2019-12-04
BR112019015600A2 (pt) 2020-03-17
CA3052090A1 (en) 2018-08-02
SG11201906973TA (en) 2019-08-27
US20190352616A1 (en) 2019-11-21
EP3574090A4 (en) 2021-01-06
JP2020505049A (ja) 2020-02-20
KR20190128634A (ko) 2019-11-18
MX2019008921A (es) 2019-11-08
WO2018140973A1 (en) 2018-08-02
CN110741080A (zh) 2020-01-31
AU2018213417A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
IL268291A (en) Multiple transgene recombinant adenovirus
GB201713765D0 (en) Modified adenovirus
EP3630987A4 (en) Recombinant adenoviruses carrying transgenes
EP3221456A4 (en) Genome-modified recombinant adeno-associated virus vectors
BR112021018704A2 (cg-RX-API-DMAC7.html)
GB201719557D0 (en) Polypeptide
IL276535A (en) adapted adenoviruses
HUE064133T2 (hu) Kutya adenovírus vektor
ZA201904705B (en) Recombinant bcg overexpressing phop-phor
SG11202101391WA (en) Recombinant lectin variants
IL272655A (en) Recombinant adeno-associated vectors
GB201810052D0 (en) Polypeptide
HK40024484A (en) Multiple transgene recombinant adenovirus
HK40018034A (en) Multiple transgene recombinant adenovirus
HK40027546A (en) Recombinant adenoviruses carrying transgenes
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
HK40031536A (en) Recombinant adeno-associated vectors
GB201814414D0 (en) Concept 36a
GB201806655D0 (en) Polypeptide
GB201810552D0 (en) Stiffening dispersion
GB201614607D0 (en) Modified adenovirus
GB201807085D0 (en) Concept 36a
GB201708471D0 (en) Polypeptide
CN304997973S (cg-RX-API-DMAC7.html)